Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

计划入组 605 人 · 首次发布于 2024 年 8 月 21 日

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

计划入组 579 人 · 首次发布于 2024 年 3 月 4 日

A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

计划入组 605 人 · 首次发布于 2026 年 9 月 8 日

immunoglobulin A antibody

Sparsentan(Filspari)

C₃₂H₄₀N₄O₅S

immunoglobulin A monoclonal antibody

A&A SMALL CHANGES HANDYPEOPLE

United States

Novozymes A/S

Denmark

Ambu A/S

Denmark

Calliditas Therapeutics Presents New NefIgArd Trial Data Supporting Nefecon's Gut-Targeted Mechanism in IgA Nephropathy

FDA Grants Accelerated Approval to Otsuka's Voyxact for IgA Nephropathy, First APRIL-Targeting Therapy

FDA Grants Breakthrough Therapy Designation to OMS721 for IgA Nephropathy